Merck Trial Shows Infants Protected From RSV by Antibody-Based Vaccine

Merck announced that its investigational monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease met its primary safety and efficacy endpoints.
Source: Drug Industry Daily